Generated by AI
Relay Therapeutics Inc. is a clinical-stage precision medicines company focused on discovering and developing small-molecule therapies for oncology and genetic disease. The company uses its proprietary Dynamo platform to combine computational modeling, structural biology, medicinal chemistry, and experimental biology in order to address protein targets that have been difficult to drug with conventional methods. Its current pipeline centers on targeted cancer programs, including candidates for genetically defined tumors, as well as selected genetic disease applications. Relay Therapeutics Inc. operates in the biopharmaceutical sector with a strong emphasis on precision oncology, where it aims to design more selective therapies for molecularly characterized diseases. Based in Cambridge, Massachusetts, the company works at the intersection of drug discovery technology and clinical development, making it a notable participant in the small-molecule precision medicine market.
Website60 Hampshire Street
Cambridge, MA, 02139
United States
The latest articles about RLAY.
Summary of Oct 15's posts. Generated by AI.
Summary of May 19's posts. Generated by AI.
Summary of Oct 15's posts. Generated by AI.
Investors talking about RLAY also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.